Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

Arvinas, Inc. and Pfizer Inc. have exciting news to share with the medical community and breast cancer patients. The two companies will be presenting updated Phase 1/2 data for their novel oral PROTAC® estrogen receptor (ER) degrader, vepdegestrant (ARV-471), at the upcoming 2023 European Society for Medical Oncology (ESMO) Annual Congress in Madrid, Spain.

Vepdegestrant is being jointly developed by Arvinas and Pfizer for the treatment of patients with locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. The Phase 1/2 data update will be presented by Dr. Erika P. Hamilton during a poster session on October 21, 2023.

The preclinical studies of vepdegestrant have shown promising results. It demonstrated up to 97% ER degradation in tumor cells and induced robust tumor shrinkage when used as a single agent in multiple ER-driven xenograft models. Furthermore, vepdegestrant exhibited increased anti-tumor activity compared to the standard of care agent, fulvestrant, both as a single agent and in combination with a CDK4/6 inhibitor.

Arvinas and Pfizer’s collaboration on vepdegestrant began in July 2021, with both companies equally sharing worldwide development costs, commercialization expenses, and profits. This partnership highlights their commitment to improving the lives of patients suffering from debilitating and life-threatening diseases.

Arvinas, a clinical-stage biotechnology company, is dedicated to discovering, developing, and commercializing therapies that degrade disease-causing proteins. They utilize their proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, which selectively and efficiently degrade and remove disease-causing proteins.

Pfizer Oncology, on the other hand, is focused on advancing medicines that make a meaningful difference in the lives of people living with cancer. With an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars, Pfizer Oncology covers a wide range of indications, including breast, genitourinary, colorectal, blood, lung cancers, and melanoma.

Both Arvinas and Pfizer are committed to pushing the boundaries of scientific research and development to bring innovative therapies to patients in need. Their collaboration on vepdegestrant exemplifies their dedication to finding new treatment options for breast cancer patients.

The presentation of updated Phase 1/2 data for vepdegestrant at the 2023 ESMO Annual Congress is an exciting milestone in the development of this potential treatment. The positive results from preclinical studies and the ongoing clinical trials provide hope for patients with locally advanced or metastatic ER+/HER2- breast cancer.

As Arvinas and Pfizer continue their collaborative efforts, they aim to address the unmet needs of patients and contribute to the advancement of cancer treatment. The progress made with vepdegestrant brings us one step closer to a future where breast cancer patients have more effective and targeted therapies available to them.

For more information on the ESMO Congress and the presentation of vepdegestrant data, please visit the official ESMO Congress website. To learn more about Arvinas and their innovative approach to protein degradation, visit www.arvinas.com. For information on Pfizer Oncology and their commitment to improving the lives of cancer patients, please visit www.Pfizer.com.